<a href="https://www.fiercebiotech.com/biotech/compass-therapeutics-stock-heads-south-after-cancer-bispecific-misses-overall-survival" hreflang="en">Compass Therapeutics’ stock heads south after cancer bispecific misses on overall survival</a>
Compass Therapeutics' stock plummeted by 53% after its bispecific antibody, tovecimig, failed to meet the overall survival endpoint in a phase 2/3 study for advanced biliary tract cancer, despite showing some improvements in progression-free survival. The company plans to discuss the data with the FDA as it prepares for a potential approval filing, but analysts express concerns about the implications of the survival miss on the drug's approvability.
Compass Therapeutics' recent phase 2/3 trial results for their bispecific antibody, tovecimig, highlight the critical importance of robust clinical trial design, especially in managing crossover effects that can obscure overall survival (OS) outcomes. This case underscores the potential for significant stock price volatility based on trial readouts and suggests that, for investors and stakeholders in biotech, carefully scrutinizing trial methodologies and anticipating regulatory challenges are crucial for informed decision-making, particularly when considering investments or collaborations in biotherapeutics with complex trial designs.